Clinical trial

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

NCT04840979

Study summary

ClinicalTrials.gov

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention 11C-ER176 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention 18F-florbetaben Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-05-11

PhasePHASE2

Conditions

Alzheimer Diseaseverified · MONDO: Alzheimer disease

Interventions

11C-ER176DRUG

18F-florbetabenDRUG

Sponsors & collaborators

Columbia Universitylead sponsor

National Institute on Aging (NIA)collaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04840979 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.